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ABSTRACT 
  
 
The European Society for Blood and Marrow Transplant Research data set was used to retrospectively analyze the 
outcomes of hypomethylating therapy (HMA) compared with those of conventional chemotherapy (CC) 
 before hematopoietic stem cell transplantation (HSCT) in 209 patients with advanced myelodysplastic syn- dromes. 
Median follow-up was 22.1 months and the median age of the group was 57.6 years with 37% of the population older than 
> 60 years. The majority of patients (59%) received reduced-intensity conditioning and 34% and 27% had intermediate-2 
and high international prognostic scoring system (IPSS) scores. At time of HSCT, 32% of patients did not achieve complete 
remission (CR) and 13% had primary refractory disease. On univariate analysis, outcomes at 3 years were not significantly 
different between HMA and CC for overall survival (OS), relapse-free survival (RFS), cumulative incidence of relapse 
(CIR), and nonrelapse mortality (NRM): OS (42% versus 35%), RFS (29% versus 31%), CIR (45% versus 40%), and NRM 
(26% versus 28%). Comparing characteristics of the groups, there were more patients < 55 years old, more patients in CR 
(68% versus 32%), and fewer patients with primary refractory disease in the CC group than in the HMA group (10% 
versus 19%, P < .001). Patients with primary refractory disease had worse outcomes than those in CR with regard to OS 
(hazard ratio [HR], 2.42; 95% confidence interval [CI], 1.41 to 4.13; P ¼ .001), RFS (HR, 2.27; 95% CI, 
1.37 to 3.76; P ¼ .001), and NRM (HR, 2.49; 95% CI, 1.18 to 5.26; P ¼ .016). In addition, an adverse effect of IPSS- 
R cytogenetic risk group was evident for RFS. In summary, outcomes after HSCT are similar for patients receiving HMA 
compared with those receiving CC, despite the higher proportion of patients with primary refractory disease in the HMA 
group. 
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INTRODUCTION 
Myelodysplastic syndromes (MDS) are potentially life- threatening clonal hematological disorders for which hematopoietic 
stem cell transplantation (HSCT) is the only curative therapy. The advent of reduced-intensity protocols has expanded the 
applicability of this procedure to those of advanced age and those who have comorbidities. This is particularly relevant given the 
older median age of the ma- jority of the population diagnosed with MDS. Current data suggest that transplantation outcomes are 
influenced by a number of factors, with pretransplantation blast percentage, cytogenetic risk group, and remission status 
considered of particular importance. Traditional attempts to provide pre- transplantation therapy for this group of patients have 
centered on the use of conventional induction chemo- therapy, a process which may not be tolerated by those of advanced age or 
with significant other comorbidities. The demonstration of the utility of azacitidine (AZA) and other hypomethylating (HMA) 
agents for the treatment of higher risk MDS in recent years [1,2] has provided an alternative approach to pretransplantation 
induction therapy. Potential advantages include decreased toxicity and provision of time while an appropriate HLA-matched 
donor is identified. The impact of pre-HSCT AZA has been assessed in a limited number of studies [3-7], but these are 
retrospective and most include small numbers of patients. Overall, these appear to demonstrate similar overall survival (OS), 
relapse-free sur- vival (RFS), relapse, and nonrelapse mortality (NRM) in pa- tients receiving AZA compared with those who 
received traditional induction chemotherapy. To contribute to the debate in this area, we conducted a large retrospective analysis 
of patients with advanced MDS referred to the Eu- ropean Society for Blood and Marrow Transplant Research (EBMT) registry 
between 2004 and 2011. 
  
METHODS 
The EBMT data set was retrospectively analyzed to assess the outcomes of patients receiving HMA compared with 
those treated with conventional chemotherapy (CC) before HSCT. HMA was approved in early 2000; conse- quently, we 
selected MDS patients who received their first allogeneic stem cell transplantation between 2004 and 2011 reported to 
the EBMT. To include a homogeneous group of patients with blasts at time of diagnosis, we included only patients 
classified as having either refractory anemia with excess blasts or refractory anemia with excess blasts in transformation 
at 
time of diagnosis, with sufficient data on anthracycline-containing chemo- therapy (n ¼ 132) or HMA (n ¼ 77). As the 
aim was to compare conventional induction chemotherapy with HMA, patients receiving only cytarabine (ara-C) were 
excluded from the analysis. 
Variables analyzed included remission status at time of HSCT, donor type (HLA-identical sibling versus unrelated 
donor), conditioning type (myeloablative [MAC] versus reduced-intensity [RIC]), age, calendar period of 
transplantation, the presence of normal versus abnormal cytogenetics (normal being defined as 46 XX or XY and 
abnormal as all other karyotypic abnormalities), and international prognostic scoring system (IPSS) score [8] at 
diagnosis and at time of transplantation. Because of the recent intro- duction of the Revised International Prognostic 
Scoring System (IPSS-R) [9], patients were additionally classified according to this model and results analyzed 
according to IPSS-R category. 
 
Statistical Methodology 
OS was defined as time between transplantation and death or last follow-up for patients alive (censored). RFS was 
defined as time between transplantation and first relapse or death without relapse, or last follow-up for patients alive 
relapse-free (censored). OS and RFS probabilities were estimated by the Kaplan-Meier estimator and compared in 
univariate analysis by the log-rank test. Relapse and nonrelapse death were analyzed as competing risks, the 
cumulative incidence rates were estimated applying the proper nonparametric estimator, and the univariate 
comparisons were done using the Gray test. All variables considered in univariate analysis were candidates to enter the 
multivariate model as adjustment factors, together with the treatment group. The latter was retained even if not 
significant, and for the others, only the significant variables were included in the final model. All endpoints were 
analyzed in multivariable analysis applying Cox regression. The difference of characteristics between groups were 
assessed by the Fisher exact test or the chi-squared test (categorical variables) or by the Mann-Whitney or Kruskal-
Wallis test (continuous variables). 
 
RESULTS 
Patients 
Patient characteristics for the 2 groups are presented in Table 1. The median follow-up of the cohort was 22.1 months (95% 
confidence interval [CI], 16.8 to 31.3) and the median age of the population was 57.6 years (range, 20.0 to 69.6). The majority of 
patients were male (n 120, 57.4%) and 37% of the population was older than 60 years. Seventy-seven pa- tients (37%) 
received HMA and 132 (63%) received CC. Donors were HLA identical in 92 (44%) and matched unrelated in 117 (56%). One 
hundred twenty-four (59%) patients received a RIC HSCT. At the time of HSCT, 55% of patients were in complete 
remission (CR), with 32% not in morphological CR and 13% of patients with primary refractory disease. Of note, there were 
more patients in the CC group in CR at the time of HSCT (68% in CC group versus 32% in HMA group, P < .001). When 
comparing the median age between the 2 groups, 
although  the  difference  in  medians  is  small  (56.8  versus 
58.8), the CC group had significantly more younger patients (P .024) than the HMA group. There were no significant differences 
between the 2 groups with regard to gender, type of donor (sibling versus HLA-matched unrelated donor), type of 
transplantation conditioning (MAC versus RIC), percentage of patients with normal cytogenetics, or IPSS 
score at diagnosis. In contrast, for the IPSS score at HSCT, the CC group had fewer patients with high or intermediate-2 IPSS 
and more patients with low IPSS compared with the HMA group (P .005). Analysis of treatment calendar period divided into 
those treated before 2007 and those treated after 2007 indicated that a greater proportion of patients treated with HMA (96% 
of HMA patients versus 78% of CC patients) were treated after 2007 (P < .001). 
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Table 1 
Patient Characteristics 
Characteristic HMA CC P Value 
 
for RFS) (Figure 2). In terms of overall relapse risk, there was 
no significant difference for those with primary refractory 
disease when compared to those in CR (P ¼ .30), though in 
  
 
difference  is  explained  by  the  significantly  higher  risk  of 
 
 
 
 
netics, and IPSS at diagnosis or at HSCT did not affect OS, RFS, 
 
 
 
 
 
 
 
diagnosis 
Low/int-1 16 (25) 16 (17) 
Int-2 27 (42) 43 (45) 
High 21 (33) 36 (38) 
IPSS at HSCT 
Low/int-1 
 
13 (34) 
 
41 (65) 
.005 
Int-2 13 (33) 8 (13)  
High 13 (33) 14 (22)  
IPSS-R 
Good 
 
32 (46) 
 
72 (62) 
 
.009 
Intermediate 18 (26) 21 (18) .267 
(monotonic) 
Poor 15 (22) 9 (8) 
Very poor 4 (6) 14 (12) 
 
group  were  identified;  however,  numbers   in   the   poor 
(n   24) and very-poor (n   18)  categories were small. In    
view of this, these categories were combined for further 
analysis, revealing a greater proportion of patients with 
worse IPSS-R in the  HMA  group  than  in  the  CC  group  
(P .06). Although not monotonic  when  considering  the 
good and intermediate groups, significant differences were 
apparent with regard to the use of cytogenetic risk groups 
with poorer outcomes demonstrated in the poor/very poor 
categories. The 3-year OS and RFS in the very poor/poor 
group were 28% (95% CI, 11% to 45%) and 12% (95% CI, 0 to 
Treatment 
 
 
 
 
MUD indicates matched unrelated donor; int, intermediate. 
Data presented are n (%), unless otherwise indicated. 
<.001 25%), respectively, compared with 55% (95% CI, 37% to 74%) 
and 50% (95% CI, 33% to 68%) in the intermediate group, and 
43% (95% CI, 31% to 56%) and 35% (95% CI, 23% to 46%) in the 
good-risk group. Reasons for better outcomes in the inter- 
mediate than in the good-risk group are attributable to 
worse NRM in the good-risk group. NRM at 3 years in the 
good-risk group was 32% (95% CI, 21% to 42%) compared with 
14% (95% CI, 3% to 26%) in the intermediate-risk group. For 
 
Survival, Relapse, and NRM 
OS and RFS did not differ between the 2 groups (Figure 1), 
with an estimated 3-year OS and RFS of 41% (95% CI, 31% to 
51%) and 36% (95% CI, 27% to 46%) for the CC group and 42% 
(95% CI, 26% to 57%) and 29% (95% CI, 16% to 42%) for the HMA 
group, respectively. The cumulative incidence of relapse 
(CIR) was 38% at 3 years for the CC group and 45% for the 
HMA group (P .633, Gray test) (Figure 1). Similarly, there 
was no significant difference in NRM between the 2 groups, 
with NRM at 3 years being 26% in the HMA group (95% CI, 14% 
to 38%) and 26% in the CC group (95% CI, 18% to 35%). On 
univariate analysis, when compared with patients in CR, 
those with primary refractory disease had worse outcome in 
terms of OS and RFS (hazard ratio [HR], 2.42; 95% CI, 1.41 to 
4.13; P ¼ .00 for OS and HR, 2.27; 95% CI, 1.37 to 3.76; P ¼ .001 
relapse, outcomes worsened with increasing cytogenetic risk 
category: 3-year relapse rates were 34% (95% CI, 23% to 45%), 
36%  (95%  CI,  19%  to  52%),  and  61%  (95%  CI,  44%  to  78%) 
for good, intermediate, and poor/very poor categories, 
respectively. 
 
Multivariate Analysis 
In multivariate analysis (Table 2), the effect of primary 
refractory disease on outcomes when compared with pa- 
tients in CR was retained as described in the univariate 
analysis: HR for OS, 2.93 (95% CI, 1.63 to 5.27; P <.001), HR for 
RFS, 2.56 (95% CI, 1.48 to 4.45; P .001), HR for relapse, 2.32 
(95% CI, 1.10  to 4.88; P .027), and HR for NRM, 2.9 (95% CI, 
1.28 to 6.58; P .011). Inclusion of the IPSS-R (Table 2) in the 
model (when compared to good) influenced RFS and relapse 
but not other outcomes: HR for RFS, 1.61 (95% CI, 1.03 to 2.52; 
P     .038)  and  HR  for  relapse,  2.33  (95%  CI,  1.31   to  4.14; 
P .004). It is to be noted that the role of refractory disease 
becomes insignificant in the multivariate model for relapse 
when IPSS-R cytogenetic risk groups are included. 
 
DISCUSSION 
Herein, we present the results of a large retrospective 
analysis by the Chronic Malignancies Working Party of the 
EBMT demonstrating equivalent outcomes for either 
period  
2004-2007 3 (4) 29 (22) 
2007-2009 29 (38) 52 (39) 
2009-2011 45 (58) 51 (39) 
 
Patients, n 77 (37) 132 (63)  terms of instantaneous risk, there is a significant difference 
Age, median 
(range), yr 
58.8 (24.9-69.6) 56.8 (20.0-69.2) .024 (Cox model: HR, 2.09; 95% CI, 1.05 to 4.16; P ¼ .035). This 
Gender   
.773 NRM in those with primary refractory disease (HR, 2.49; 95% 
Male 43 (56) 77 (58)  
Female 34 (44) 55 (42) CI, 1.18 to 5.26; P ¼ .016). Patients not in CR but without 
Stage at HSCT   .001 primary refractory disease had similar outcomes compared 
CR 25 (32) 90 (68) with those in CR. Donor type, conditioning regimen (MAC 
No CR 37 (48) 29 (22) versus RIC), presence of normal versus abnormal cytoge- 
Primary 15 (20) 13 (10)  
refractory     
Donor .204 CIR, or NRM. Additionally, no statistically significant effect on 
HLA sibling 29 (38) 63 (48) outcomes was noted in regard to age (analyzed as a contin- 
MUD 48 (62) 69 (52) uous variable) or calendar period of HSCT. 
Conditioning   .090 
MAC 25 (32) 60 (45)  
RIC 52 (68) 72 (55) Effect of IPSS-R Cytogenetic Grouping 
Cytogenetics   .509 Adequate data were available in 185 of the 209 patients to 
Normal 32 (43) 60 (49) be able to classify patients according to IPSS-R cytogenetic 
Abnormal 42 (57) 62 (51) grouping (Table 1). Using this classification, no differences in 
IPSS at 
.444 
HMA and CC groups in regard to IPSS-R cytogenetic risk 
 
  
 
 
 
Figure 1. Outcomes for hypomethylating agents compared with chemotherapy. (A) Shows overall survival, (B) relapse-free survival, (C) cumulative incidence of 
relapse, and (D) nonrelapse mortality. 
 
 
pretransplantation HMA or CC. This is particularly notable, 
given the low number of patients in the HMA group who 
achieved CR and the younger age of those in the CC group. In 
addition, there was a slight increase in the proportion of 
those with worse cytogenetics per the IPSS-R classification in 
the HMA group. Previous studies have also demonstrated 
similar equivalence of these 2 modalities of pre- 
transplantation induction therapy, although only 1 directly 
looking at this issue is of a similar size [4]. In that study, the 
reported 3-year  OS  and  RFS  rates  for  HMA  and  CC  
(58% versus 51% for OS and 52% versus 45% for RFS) were 
higher than those reported here (42% versus 41% for OS, and 
29% versus 36% for RFS). The reasons for this difference are 
unclear; however, they are likely to reflect differences 
between the 2 patient populations. For example, in the 
Damaj study, 74% of patients were reported to have < 5% 
blasts before HSCT compared with only 55% of patients in our 
study considered to be in CR. Overall outcomes are similar to 
that reported by other groups of outcomes after HSCT for 
advanced MDS [7,10,11]. 
The recent publication of the cytogenetic scoring system 
used in IPSS-R [12] provided an improved method of pre- 
dicting outcomes for patients with MDS in both general and 
transplantation settings [13,14]. None of the other analyses of 
pretransplantation HMA have included this scoring system; 
hence, we attempted to review its utility in our patient 
cohort. Although small numbers meant the poor and very 
poor groups had to be combined for analysis, we 
  
 
 
 
Figure 2. Outcomes according to disease status before HSCT. (A) Shows overall survival and (B) shows relapse-free survival. 
 
 
demonstrate a significant adverse effect of adverse cytoge- netics on relapse and RFS, underlying the importance of considering the 
pretransplantation karyotype on prognosis. The relapse incidence of 61% at 3 years in these patients, along with currently reported 
poor outcomes in those who relapse after transplantation [15,16], indicates the urgent  need for strategies directed at prevention of 
post-HSCT relapse. 
The influence of CR status is interesting. A minimal pre- transplantation disease burden is considered important for post-
transplantation outcomes [17,18], and the presence of more than 5% blasts at time of HSCT is reported to contribute to poor results 
[19]. Whether this reflects the pre- transplantation therapy or an inherent biological sensitivity that is more likely to result in 
favorable outcomes after HSCT remains uncertain. In our analysis, 48% of the HMA group and 22% of the CC group were not in CR 
at the time of HSCT. Unlike for patients with primary refractory disease, on uni- variate analysis, the outcomes of patients not in 
CR could not be demonstrated to be significantly worse than those in CR before HSCT. This potentially explains the equivalent 
outcomes in the HMA and CC groups despite the higher proportion of patients not in CR in the HMA group at the time of HSCT. A 
recent publication by a French group demon- strated no difference in post-HSCT outcomes when AZA was compared with the 
best supportive care before HSCT [20]. Furthermore, given evidence that a number of patients potentially suitable for 
transplantation submitted to prein- duction therapy do not reach transplantation [21], it may be that an upfront HCST approach 
is preferable for selected patients. This further complicates an area where, for many groups, some form of pretransplantation 
induction therapy is now considered standard. Although beyond the scope of our study, prospective delineation of factors that 
identify the most appropriate type of pretransplantation therapy are required. In the absence of these, a recently published algo- 
rithm contributes further to this debate [22]. 
 
On multivariate analysis, the major factor affecting out- comes was the presence of primary refractory disease, although worsening 
IPSS-R cytogenetics could be demon- strated to have an effect of RFS and CIR. The adverse effect of primary refractory disease is in 
line with that reported in other studies. Notably, these patients had an increased NRM and it is possible that there is no advantage for 
ongoing at- tempts at induction therapy for this subgroup of patients if the only result is increased toxicity. Novel transplantation 
approaches and/or the use of directed therapy, such as post- HSCT donor lymphocyte infusion, are required to improve outcomes in 
these patients. The adverse effect of worsening IPSS-R cytogenetics in our analysis was limited by small numbers; however, a recently 
published large EBMT analysis confirms the impact of IPSS-R cytogenetics on OS and CIR and additionally on OS [14]. That study also 
reported a significant effect of monosomal karyotype within the poor risk category, a factor that could not be analyzed in this study. 
Although this study includes a large number of patients, it is limited by the retrospective nature of the analysis and some missing 
data points. Because we only have information on those patients who underwent transplantation, we do not attempt to draw 
conclusions on all patients treated and, therefore, are unable to provide information on outcomes of patients who received either 
HMA or CC but failed to proceed to transplantation. Furthermore, it is not known why centers decided for CC or HMA and detailed 
information on comor- bidities influencing the choice of pre-HSCT therapy was not available. 
In conclusion, despite the above limitations, this large study provides further weight with regard to the accumu- lating 
evidence that pre-HSCT HMA or CC results in equivalent post-transplantation outcomes. Furthermore, we suggest that other 
prognostic factors such as adverse cyto- genetics or primary refractory disease are far more relevant to outcome than type of 
prior transplantation therapy. Pro- spective trials with accompanying translational studies are 
  
 
Table 2 
Results of Multivariate Analysis 
Outcome HR P Value 95% CI 
Overall survival 
Treatment 
3. 
Gerds AT, Gooley TA, Estey EH, et al. Pretransplantation therapy with 
azacitidine vs induction chemotherapy and posttransplantation 
outcome in patients with MDS. Biol Blood Marrow Transplant. 2012;18: 
1211-1218. 
4. Damaj G, Duhamel A, Robin M, et al. Impact of azacitidine before 
allogeneic stem-cell transplantation for myelodysplastic syndromes: a 
 
Oncol. 2012;30:4533-4540. 
d before allogeneic hematopoietic cell transplantation. Bone Marrow 
 
 
 
 
 
 
2079-2088. 
 
 
 
IPSS-R 
Good 1.00 d d 
Intermediate .65 .126 .37-1.13 
2454-2465. 
 
transplantation for patients 50 years or older with myelodysplastic 
syndromes or secondary acute myeloid leukemia. J Clin Oncol. 2010;28: 
405-411. 
 
 
 
 
 
cation, monosomal karyotype, and outcome after hematopoietic cell 
d 2012;120:1398-1408. 
 
Relapse 
Treatment 
HMA 1.00 d d 
CC .98 .945 .54-1.78 
Stage 
CR 1.00 d d 
No CR 1.46 .206 .81-2.65 
Primary refractory 1.63 .259 .70-3.80 
IPSS-R 
Good 1.00 d d 
Intermediate .89 .733 .44-1.77 
Poor/very poor 2.33 .004 1.31-4.14 
 
  
 
 
required to confirm these results and provide further infor- 
mation with regard to individual factors that may direct the 
most appropriate choice of pretransplantation therapy. 
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